Business Wire12.03.19
Aperio Clinical Outcomes, a clinical research organization (CRO), has appointed Cari Kniola, director of Corporate Strategy, to lead Aperio’s strategy for their existing and continued growth.
Kniola has more than 20 years of clinical research experience in the medical device and pharmaceutical industries, ranging from a clinical research associate through project management of global studies at both sponsor companies and CROs. This experience is combined with an appreciation for Aperio’s culture and the need to preserve it as the company continues to grow and evolve. This strategic growth occurs as Aperio continues to match pace with a clinical research industry experiencing emerging technologies, novel treatments and an ever-changing regulatory landscape. Kniola will lead through oversight of proposal and marketing strategy, strategic business development and service partnerships.
Faye Woolf, Aperio’s founder and CEO, said, “We want to make sure to continue to grow Aperio in a way that maximizes our potential while being true to who we are, all the while providing our services with the utmost quality and integrity. We are so fortunate to have Cari’s natural inclination towards strategy and creative solutions coupled with a vast background in the industry to ensure we maintain our core principles as Aperio makes its mark in the industry.”
“My entire career has been involved in clinical research, and I thrive on the creative process and seeing strategic visions come to fruition,” said Kniola. “I am excited to take both my ‘real world’ experience and my skills and use them together to help strategize the growth of Aperio. We have a team of people at Aperio who are passionate about what they do, with an amazing depth and breadth of experience in clinical development. With our high caliber teams, our culture of quality and transparency, and our ability to evolve as the industry evolves, the possibilities are limitless for Aperio’s continued growth as an agile and innovative CRO services provider.”
In a data driven industry, Aperio remains dedicated to transparency with clients and focused on the most important part of the process: people. Aperio provides full, customizable clinical research services across multiple therapeutic areas, as well as consulting services in quality assurance, strategic resourcing, and clinical trial technology.
Kniola has more than 20 years of clinical research experience in the medical device and pharmaceutical industries, ranging from a clinical research associate through project management of global studies at both sponsor companies and CROs. This experience is combined with an appreciation for Aperio’s culture and the need to preserve it as the company continues to grow and evolve. This strategic growth occurs as Aperio continues to match pace with a clinical research industry experiencing emerging technologies, novel treatments and an ever-changing regulatory landscape. Kniola will lead through oversight of proposal and marketing strategy, strategic business development and service partnerships.
Faye Woolf, Aperio’s founder and CEO, said, “We want to make sure to continue to grow Aperio in a way that maximizes our potential while being true to who we are, all the while providing our services with the utmost quality and integrity. We are so fortunate to have Cari’s natural inclination towards strategy and creative solutions coupled with a vast background in the industry to ensure we maintain our core principles as Aperio makes its mark in the industry.”
“My entire career has been involved in clinical research, and I thrive on the creative process and seeing strategic visions come to fruition,” said Kniola. “I am excited to take both my ‘real world’ experience and my skills and use them together to help strategize the growth of Aperio. We have a team of people at Aperio who are passionate about what they do, with an amazing depth and breadth of experience in clinical development. With our high caliber teams, our culture of quality and transparency, and our ability to evolve as the industry evolves, the possibilities are limitless for Aperio’s continued growth as an agile and innovative CRO services provider.”
In a data driven industry, Aperio remains dedicated to transparency with clients and focused on the most important part of the process: people. Aperio provides full, customizable clinical research services across multiple therapeutic areas, as well as consulting services in quality assurance, strategic resourcing, and clinical trial technology.
